A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

NCT07332533 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

490

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Gastric Cancer

Interventions

DRUG: KN026
DRUG: Capecitabine
DRUG: Enlonstobart
DRUG: Oxaliplatin
DRUG: Trastuzumab
DRUG: Pembolizumab
DRUG: Cisplatin
DRUG: Fluorouracil

Sponsor

Shanghai JMT-Bio Inc.